35 completed. 35 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 35 |
| Phase 2 | 3 | Completed 3 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets - Myelofibrosis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 105 | 2021-02-05 | 2023-11-13 |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis Placebo for Navitoclax, Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 3 | Completed | AbbVie | 252 | 2020-09-29 | 2026-03-23 |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) Momelotinib, Placebo to match danazol, Danazol - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 195 | 2020-02-07 | 2023-11-01 |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB, Best Available Therapy (BAT) - Primary Myelofibrosis, Post-Polycythemia Vera | Phase 3 | Completed | Celgene | 202 | 2019-09-09 | 2025-08-28 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 21 | 2018-03-28 | 2026-07-17 |
| Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Momelotinib, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 156 | 2014-06-19 | 2023-05-23 |
| A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Ruxolitinib - Primary Myelofibrosis (MF) | Phase 3 | Completed | Novartis Pharmaceuticals | 51 | 2014-04-01 | 2016-07-11 |
| Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Momelotinib, Ruxolitinib, Placebo to match momelotinib - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 432 | 2013-12-06 | 2023-05-12 |
| Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy Eltrombopag Olamine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 21 | 2012-01-13 | 2023-09-26 |
| A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms PegIntron, Pegasys, Hydrea - Polycythemia Vera, Essential Thrombocythemia | Phase 3 | Completed | Thomas Stauffer Larsen | 202 | 2012-01-01 | 2022-04-27 |
| INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. INC424 - Myelofibrosis | Phase 3 | Completed | Novartis Pharmaceuticals | 2233 | 2011-08-16 | 2019-04-26 |
| Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Pomalidomide 0.5 mg, Placebo, Pomalidomide - Primary Myelofibrosis, MPN-associated Myelofibrosis | Phase 3 | Completed | Celgene | 267 | 2010-09-08 | 2019-07-17 |
| COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Ruxolitinib, Placebo - MPN (Myeloproliferative Neoplasms) | Phase 3 | Completed | Incyte Corporation | 309 | 2009-08-01 | 2018-03-12 |
| Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Ruxolitinib, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Completed | Novartis Pharmaceuticals | 219 | 2009-07-01 | 2019-08-19 |
| American Ginseng in Treating Patients With Fatigue Caused by Cancer American ginseng, placebo - Chronic Myeloproliferative Disorders, Fatigue | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 364 | 2008-10-01 | 2017-02-09 |
| Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder cyclosporine ophthalmic emulsion, placebo - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 3 | Completed | Vanderbilt-Ingram Cancer Center | 164 | 2008-10-01 | 2017-03-07 |
| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications internet-based intervention, questionnaire administration, psychosocial assessment and care - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 3 | Completed | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 1337 | 2008-08-01 | 2012-03-07 |
| A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families educational intervention, informational intervention, internet-based intervention - Chronic Myeloproliferative Disorders, Leukemia | Phase 3 | Completed | Tufts Medical Center | 198 | 2008-06-01 | 2011-07-13 |
| Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial educational intervention - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 3 | Completed | Case Comprehensive Cancer Center | 583 | 2008-04-01 | 2020-07-27 |
| Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Fentanyl sublingual spray, Placebo - Cancer | Phase 3 | Completed | INSYS Therapeutics Inc | 130 | 2007-10-01 | 2014-03-05 |
Showing 20 of 35. Sign in to see all of them.
Leukemia, Myeloid, Accelerated Phase (20) · Leukemia, Myeloid, Chronic-Phase (20) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Blast Crisis (19) · Burkitt Lymphoma (19) · Leukemia, Lymphocytic, Chronic, B-Cell (19) · Lymphoma, Non-Hodgkin (19) · Leukemia, Myeloid, Acute (18) · Lymphoma, B-Cell, Marginal Zone (18) · Lymphoma, Follicular (18) · Lymphoma, Large B-Cell, Diffuse (18) · Lymphoma, Large-Cell, Immunoblastic (18) · Lymphoma, Mantle-Cell (18) · Myeloproliferative Disorders (18)
Hemic and Lymphatic Diseases (35) · Bone Marrow Diseases (34) · Hematologic Diseases (34) · Chronic Disease (22) · Disease Attributes (22) · Leukemia, Myeloid (22) · Neoplasms by Histologic Type (22) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Immune System Diseases (21) · Immunoproliferative Disorders (21) · Leukemia, Lymphoid (21) · Lymphatic Diseases (21) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (20) · Carcinogenesis (19)
ruxolitinib (6) · Cyclophosphamide (3) · Early Intervention, Educational (3) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (3) · Hydroxyurea (2) · Peripheral Blood Stem Cell Transplantation (2) · Psychiatric Rehabilitation (2) · Whole-Body Irradiation (2) · liposomal amphotericin B (2) · Acyclovir (1) · Antilymphocyte Serum (1) · Asian ginseng (1) · Busulfan (1) · Captopril (1) · Carboplatin (1)
Novartis Pharmaceuticals (4) · Fred Hutchinson Cancer Center (3) · Sierra Oncology LLC - a GSK company (3) · Alliance for Clinical Trials in Oncology (2) · Celgene (2) · Memorial Sloan Kettering Cancer Center (2) · Vanderbilt-Ingram Cancer Center (2) · AbbVie (1) · Case Comprehensive Cancer Center (1) · Dartmouth-Hitchcock Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · INSYS Therapeutics Inc (1) · Incyte Corporation (1)
United States (26) · Canada (10) · Germany (10) · Italy (10) · Spain (10) · Belgium (9) · France (8) · United Kingdom (8) · Australia (7) · Austria (7) · Netherlands (7) · Israel (6) · Sweden (6) · Czechia (5) · Hungary (5)
Alessandro Rambaldi, MD (1) · David J. Straus, MD (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Eduardo Bruera, MD (1) · Garrett Nichols, MD, MSC (1) · Gautam Borthakur (1) · Jeffrey H. Lipton, MD, PhD (1) · Jie Jin, PhD (1) · John A. Glaspy, MD, MPH (1) · Karen Syrjala (1) · Kenneth Meehan, MD (1)
PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 23911705, PMID 26069290, PMID 28962635, PMID 42316774, PMID 42452788, PMID 15459300, PMID 17397698, PMID 22081489, PMID 22157574, PMID 22375970, PMID 22375971, PMID 22480131, PMID 23423753, PMID 24038026, PMID 24056820, PMID 24174625, PMID 25616577, PMID 25682576, PMID 26228487, PMID 26380150, PMID 26700120, PMID 26700123, PMID 27020837, PMID 27247324, PMID 27773929, PMID 28228106, PMID 28606598, PMID 28935847, PMID 29275119, PMID 31235325, PMID 32017044, PMID 32628342, PMID 33210570, PMID 33420905, PMID 36282798, PMID 36709073, PMID 36999619, PMID 37517413, PMID 38501751, PMID 38990433, PMID 39265613, PMID 39695117, PMID 40691344, PMID 42588744, PMID 42751490
P30CA068485 (2), 2009 (1), 2018 (1), R01CA112631 (1), R01CA119196 (1), R01CA127655 (1)